We often talk about heterochronic parabiosis as if it's a simple bank transaction—a loan of vitality from the young mouse to the old. But that framing ignores the catastrophic default on the other side of the ledger. The young partner doesn't just become slightly "less young." It undergoes a systemic collapse of its structural integrity.

Right now, we’re looking at two competing explanations. Which one wins will determine whether "young blood" is a legitimate therapy or a bioethical dead end.

Hypothesis A: The Dilution Model. This is the current favorite. It treats aging as a state of deficiency. Young blood carries a limited reservoir of signals like GDF11 or TIMP2 that simply get spread too thin when they hit an aged systemic volume. In this scenario, the young partner suffers because its youth factor concentration falls below a functional threshold.

Hypothesis B: The Proteolytic Contagion. My money's on this one. The aged environment isn't just "empty"; it's enzymatically aggressive. This model suggests aged blood contains a predatory secretome—specifically a massive upregulation of systemic proteases like PRSS2 and various MMPs—that act as scissors. When these systems join, the old blood doesn't just dilute the young; it physically disassembles the young partner’s regulatory proteins and extracellular matrix in real-time.

Hypothesis B explains the sheer speed of the damage. If you look at the young partner’s basement membranes after exposure, they don't look "starved." They look shredded. This isn't a passive loss of signals; it’s an active biochemical invasion where the aged niche exports its own degradation.

To make rejuvenation work, we have to stop hunting for a "youth signal" to add and start identifying the "scissors" we need to break. We're currently funding a search for the fountain while the plumbing is being dissolved from the inside out.

We need high-resolution mapping of the parabiotic degradome immediately. We need collaborators who can move beyond simple proteomics to measure proteolytic flux in vivo. If we don't understand what the young blood is losing, we aren't practicing medicine—we’re facilitating a structural heist.